ClinicalTrials.gg
Status unknownNCT05353010Updated Apr 29, 2022

A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

A Phase 1 interventional study of Tacrolimus and IN-A001(Tegoprazan) in Healthy, sponsored by HK inno.N Corporation. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
19 Years to 45 Years
Sex
All
01

Study summary

This study aims to investigate the effect of IN-A001 50mg on the pharmacokinetics of Tacrolimus 5mg in healthy volunteers

Read the detailed description

This is a open-label, 1-sequence, 2-period, multiple oral dose, phase 1 study. Healthy subjects will be assigned to a group and sequentially administerd Tacrolimus and IN-A001.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥ 19.0 and ≤ 28.0 kg/m\^2 at the time of screening.
  2. Those who agreed to use combination of effective or medically approved method from the date of first administration of product(IP) to the end of the clinical trial (when testing for final safety evaluation).
  3. In the case of female participant, who has negative result at the hCG urine pregnancy test and is not pregnant or currently breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Has infections
  2. Has a history of
  3. Has a history of gastrointestinal disease that may affect the absorption of product.
  4. Has genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption disorder etc.
  5. History of and severe allergic reaction to any of the components of IP.
  6. Has participated in any other clinical study, etc. and received IPs within 180 days prior to the screening visit.
  7. Excessive smoking (> 10 cigarettes/day) within 14 days prior to the screening visit.
  8. Excessive drinking ((> 21 units/week) within 14 days prior to the screening visit.
  9. Has shown the following results from the laboratory test during the screening period.

    • , ALT level > 1.5 × at screening;
    • (estimated glomerular filtration rate) estimated on the basis of CKD-EPI is less than 60 mL/min/1.73 m2;
  10. Has shown the following results during the 12-lead during the screening period.

    • > 450 ms
    • Clinically significant abnormal rhythm and findings when the investigator medically determines
  11. Determined ineligible for study participation by the investigator for other reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Period 1: A; Period 2: B and C

    A: Oral Administration of Tacrolimus 5mg once / B: Oral Administration of IN-A001(Tegoprazan) 50mg QD for 7 days / C: Oral Administration of IN-A001(Tegoprazan) 50mg + Tacrolimus 5mg once

    Drug: Tacrolimus · Drug: IN-A001(Tegoprazan) · Drug: IN-A001(Tegoprazan) + Tacrolimus

Interventions

  • Tacrolimus 5mg (1 mg \* 5 capsules)

    Also known as: prograf

  • IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)

    Also known as: K-CAB

  • DrugIN-A001(Tegoprazan) + Tacrolimus

    Drug page: Tegoprazan

    IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)

    Also known as: IN-A001: K-CAB, Tacrolimus: Prograf

06

What researchers measure

Primary outcomes

  1. Cmax of Tacrolimus

    Maximum Plasma Concentration at Steady State of Tacrolimus

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

  2. Tmax of Tacrolimus

    Time to Cmax at steady state

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

  3. AUClast of Tacrolimus

    Area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

  4. AUCinf of Tacrolimus

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

  5. T1/2β of Tacrolimus

    Half-life of the drug during elimination phase

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

Secondary outcomes

  1. Point estimates and 90% CI for log (GMR of Period 2 Cmax, AUClast, AUCinf) / log (GMR of Period 1 Cmax, AUClast, AUCinf) of Tacrolimus

    log(GMR of Period 2 Cmax, AUClast, AUCinf) / log (GMR of Period 1 Cmax, AUClast, AUCinf)

    Time frame: up to 72 hours(period 1), up to 240 hours(period 2)

  2. Cmax of Tegoprazan

    Maximum Plasma Concentration at Steady State of Tegoprazan

    Time frame: up to 240 hours(period 2)

  3. Tmax of Tegoprazan

    Time to Cmax at steady state

    Time frame: up to 240 hours(period 2)

  4. AUClast of Tegoprazan

    Area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration

    Time frame: up to 240 hours(period 2)

  5. AUCinf of Tegoprazan

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: up to 240 hours(period 2)

  6. T1/2β of Tegoprazan

    Half-life of the drug during elimination phase

    Time frame: up to 240 hours(period 2)

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2022; primary completion for Jul 2022, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
Apr 29, 2022
StartEst.
May 1, 2022
Primary completionEst.
Jul 1, 2022
CompletionEst.
Nov 1, 2022
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05353010
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
May 1, 2022 (estimated)
Primary completion
Jul 1, 2022 (estimated)
Completion
Nov 1, 2022 (estimated)
Last update
Apr 29, 2022

Study contacts

Sohyun Kim
Contact
sohyun.kim21@inno-n.com
82-2-6477-0225
Nagyung Kim
Contact
nagyung.kim@inno-n.com
82-2-6477-0195
Kyun-Seop Bae, MD, PhD
principal investigator · Asan Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Tegoprazan

Start the discussion